Address: T1-14, Jaya 33, No 3, Jalan Semangat, Seksyen 13, Petaling Jaya, Selangor, 46200,Malaysia
Tel: 603 – 6209 3088
Web: http://healthcare.bayer.com/scripts/pages/en/index.php
Bayer is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. With headquarters in Leverkusen, Germany, Bayer is represented around the world with about 350 companies. The Bayer Group employs some 108,000 people worldwide. Its core businesses – Bayer Healthcare Bayer CropScience, and Bayer MaterialScience – are among the world’s leading companies in their respective fields of business.
The history of Bayer Co. (Malaysia) Sdn Bhd and its legacy companies dates back to 1967. Bayer Co. (Malaysia Sdn Bhd Houses the life sciences activities of Bayer CropScience and Bayer Healthcare. The third pillar of our activities is the Bayer Agency Business which handles the Bayer Material Science and among others the Lanxess Business in Malaysia. There are over 200 people under the company’s employ and it operates form its base in Petaling Jaya, Selangor, where also the company’s corporate functions on IT, Finance, Accounting and Corporate HR & Communication are located. With its clear focus on innovation and growth and its strategic alignment along its core activities in healthcare, nutrition and innovative materials, Bayer in Malaysia is committed to further drive progress in Malaysia for the benefits of the people and to improve Malaysians’ quality of life.
The Business Group Bayer Healthcare (formerly Bayer Schering Plough) was formed when Bayer acquired Schering AG in 2006, a speciality pharmaceutical company based in Germany, in the largest acquisition in company history. The takeover led to the formation of a powerful, leading division that ranks among the top 10 pharmaceutical specialits in the world and holds a strong position in Biologicals. In Malaysia, the integration between the two came into effect on January 1st, 2007 and created one of the leading pharmaceutical companies in the country, with a strong leadership position in the field of hormonal contraception.
Bayer Healthcare is focused on four strategic business areas: Diagnostic Imaging (contrast media for X-ray, computed tomography, magnetic resonance imaging), General Medicine (anti-infectives, hypertension and coronary heart diseases, diabetes and men’s healthcare), Speciality Medicine (oncology and specialised therapeuticals) and Women’s healthcare (hormonal contraception, menopause managmeent and gynaecological therapies).
Aside from Bayer Healthcare’s commercial activities the company is engaged in education and awareness programmes. One of these initiatives is the ‘Yes, I Can’ campaign addressing the issue of unplanned pregnancies by empowering women to make informed decisions about their sexual health and contraceptive options. It seeks to empower women of every age to make informed choices about their sexual health and contraceptive options. The campaign also addresses and tackles the issues of unplanned pregnancies and abandoned babies that has been a rising concern and the company facilitates conversations between young women and their healthcare providers about the role of contraception in reducing unplanned pregnancy.
The components of the Yes, I Can campaign include: Ambassadors with representation from Deborah Henry, Miss Malaysia World 2007, popular TV personality Julie Woon and online personality Nicole Tan (http://nicolekiss.blogspot.com); a campus roadshow: The Yes, I Can campaign roadshow will bring the campaign to young women through campus visits to key universities and colleges in the Klang Valley. A specially designed campaign website with links to Twitter and Facebook will provide a conducive online platform for young women to discuss topics related to family, love and relationship. Lending their expert opinions to the Yes, I Can campaign are healthcare professionals who will provide advice on the various topics online.There is also the The Yes, I Can challenge, which calls on Malaysian adults aged 18 and above to support and be advocates for Yes, I Can by making an impactful difference on the issue at hand.
Bayer Healthcare also engages in widening patient access through programmes such as the NexPAP Patient Assistance Programme: This program is designed to assist Malaysian patients who have been diagnosed with Hepatocellular Carcinoma (HCC) (a form of liver cancer), and have been prescribed by their doctors to use sorafenib (generic name). NexPAP aims to provide drug assistance to help patients in continuing with drug treatment for as long as medically required. This program is part of Bayer Healthcare Malaysia initiatives to provide drug assistance to Malaysian patients.
Bayer Healthcare is working in partnership with Malaysian Liver Foundation (MLF) to run NexPAP.
As part of NexPAP. patients will purchase the first two months of sorafenib, after which Bayer Schering Pharma will donate free sorafenib for up to the next 12 calendar months to patients, as long as medically required as determined by the prescribing physician.
Can you give our readers an outline of Bayer’s background in Malaysia and its current organisational division? Herbert Dittmar (HD): Bayer has been in Malaysia for around fifty years. It…
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here
